What are the proper steps for giving a patient an intramuscular Depo‑Provera (medroxyprogesterone acetate) injection with a prefilled syringe, including how to handle the large air bubble, mixing, and injection technique?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Depo-Provera IM Injection Administration Guide

For intramuscular Depo-Provera (DMPA) prefilled syringes: shake the syringe vigorously before injection to ensure uniform suspension, do NOT expel the air bubble (it ensures complete dose delivery), and inject the full 150 mg dose deep into the gluteal or deltoid muscle. 1, 2

Pre-Injection Preparation

Shaking the Suspension

  • Shake the prefilled syringe vigorously immediately before administration to ensure the medroxyprogesterone acetate suspension is uniformly mixed 1
  • The medication is a suspension (not a solution), meaning the active drug particles settle and must be resuspended for proper dosing 1
  • Inadequate mixing may result in inconsistent dosing and reduced contraceptive efficacy

The Air Bubble - Critical Point

  • Do NOT expel the air bubble from the prefilled syringe 1
  • The air bubble is intentionally included by the manufacturer to ensure delivery of the complete 150 mg dose 1
  • Expelling the air bubble will result in underdosing the patient, potentially compromising contraceptive effectiveness

Injection Technique

Site Selection and Administration

  • Administer as a deep intramuscular injection into either the gluteal or deltoid muscle 1, 2
  • The recommended dose is 150 mg administered every 3 months (13 weeks, with a grace period up to 15 weeks) 3, 4
  • Use proper IM injection technique with appropriate needle length to ensure deep muscle penetration 1

Timing and Backup Contraception

  • If starting within the first 7 days of menstrual bleeding, no backup contraception is needed 4
  • If starting >7 days since menstrual bleeding began, the patient needs backup contraception (abstinence or barrier method) for 7 consecutive days 4
  • The injection can be given at any time if you are reasonably certain the patient is not pregnant 4

Important Clinical Considerations

Counseling Points Before First Injection

  • Counsel patients about menstrual irregularities before the first injection to improve continuation rates - nearly all patients experience irregular bleeding initially, which typically improves over time and often progresses to amenorrhea 3
  • Discuss potential weight gain, though this varies significantly between individuals (21% of adolescents experience early weight gain >5% at 6 months) 3
  • Recommend calcium supplementation (at least 1300 mg daily) and vitamin D (600 IU daily) for bone health, along with weight-bearing exercise and smoking cessation 3

Follow-Up Scheduling

  • Schedule repeat injections every 11-12 weeks for adolescents to allow buffer time for missed appointments 5
  • Injections can be given up to 2 weeks late (15 weeks from last injection) without requiring additional contraceptive protection 6, 4, 7
  • If ≥2 weeks late (≥15 weeks since last injection), treat as a new start and use backup contraception for 7 days 6

Common Pitfalls to Avoid

  • Never expel the air bubble - this is the most critical technical error that leads to underdosing 1
  • Always shake vigorously - failure to adequately mix the suspension results in inconsistent dosing 1
  • Don't forget pre-injection counseling - patients counseled about side effects before first injection have better continuation rates 3
  • Ensure deep IM injection technique - subcutaneous administration of the IM formulation may affect absorption (note: a separate subcutaneous formulation exists at 104 mg dose) 5, 8

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.